Quantification of metaphyseal modeling in children treated with bisphosphonates

被引:16
作者
Ward, K
Cowell, CT
Little, DG
机构
[1] Childrens Hosp Westmead, Dept Orthopaed Res & Biotechnol, Westmead, NSW 2145, Australia
[2] Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW, Australia
[3] Childrens Hosp Westmead, Dept Endocrinol, Sydney, NSW, Australia
关键词
bisphosphonates; bone modeling; pediatrics; radiology; bone development;
D O I
10.1016/j.bone.2005.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There has been recent concern in the literature that the treatment with bisphosphonates in children can have an adverse effect on metaphyseal modeling leading to "drug-induced osteopetrosis". We created a normal database called metaphyseal index in the distal femur so that we could quantify the inwasting modeling process in children on bisphosphonates. Radiographs of the distal femur of 468 normal children who had presented to our institution for orthopedic trauma were examined. A measurement of the distal femoral growth plate width (GPW) was recorded. The femoral width at an interval of 0.5 GPW proximal to the distal femoral growth plate was also recorded (0.5 W). The metaphyseal index was defined as a ratio of 0.5 W/GPW A graph of the means, one and two standard deviations from the mean, was constructed using the data obtained from this cohort. We found this ratio to be constant with minimal variability regardless of the age or sex of the child. We plotted 20 patients at our institution given bisphospbonates for localized orthopedic complaints. Z scores for girls averaged 0.68 and boys 0.13. Three patients had Z scores > 2.0, with values of 2.2, 2.9, and 3.2. Metaphyseal modeling in the distal femur is constant, with slight variation between sexes, resulting in a similar shape of the distal femur throughout childhood. Clinically relevant doses of bisphosphonates given for appropriate indications do not necessarily disturb this process, while the beneficial clinical effect is maintained. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:999 / 1002
页数:4
相关论文
共 17 条
[1]   Use of bisphosphonate therapy for osteoporosis in childhood and adolescence [J].
Batch, JA ;
Couper, JJ ;
Rodda, C ;
Cowell, CT ;
Zacharin, M .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (02) :88-92
[2]   Juvenile spondyloarthropathies and related arthritis [J].
Bukulmez, H ;
Colbert, RA .
CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (05) :531-535
[3]  
Gandrud LM, 2003, J PEDIATR ENDOCR MET, V16, P887
[4]  
Goergens E, 2004, BONE, V34, pS78
[5]  
Kim YD, 2001, J IND ENG CHEM, V7, P1
[6]   Treatment of monostotic fibrous dysplasia with pamidronate [J].
Kos, M ;
Luczak, K ;
Godzinski, J ;
Klempous, J .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2004, 32 (01) :10-15
[7]   Learning to drive [J].
Litt, IF .
JOURNAL OF ADOLESCENT HEALTH, 2004, 34 (01) :1-1
[8]   Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats [J].
Little, DG ;
Peat, RA ;
McEvoy, A ;
Williams, PR ;
Smith, EJ ;
Baldock, PA .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (11) :2016-2022
[9]   Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis [J].
Little, DG ;
Smith, NC ;
Williams, PR ;
Briody, JN ;
Bilston, LE ;
Smith, EJ ;
Gardiner, EM ;
Cowell, CT .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (07) :1300-1307
[10]  
Percin EF, 2003, GENET COUNSEL, V14, P387